I-Mab Set to Present Givastomig Phase 1 Data at SITC 2024
Upcoming at the Society for Immunotherapy of Cancer (SITC) conference, I-Mab (NASDAQ: IMAB) will unveil crucial findings from the Phase 1 optimized dose estimation for its novel bispecific antibody, Givastomig (TJ033721/ABL111). This engagement underscores I-Mab's ongoing commitment to pioneering solutions in the immunotherapy landscape.
Details of the Presentation
I-Mab's presentation will feature vital insights regarding Givastomig, focusing on its optimized dosage and effectiveness in targeting cancer cells. The details of the presentation are as follows:
- Title: Optimal dose estimation using an integrated approach from Phase I data of Givastomig, a novel Claudin18.2×4-1BB bispecific antibody.
- Poster #: 1474
- Presenter: J.A. Yanez, I-Mab
- Session: Poster Hall, George R. Brown Convention Center
- Session Date: November 9, 2024
- Session Time: 9:00 am CDT to 8:30 pm CDT, Level 1 – Exhibit Halls AB
Attendees will be able to access the complete poster presentation on I-Mab's official website under the "Innovation, Publications & Presentations" section shortly after the event.
Understanding Givastomig
Givastomig is crafted as a bispecific antibody that effectively zeroes in on Claudin (CLDN) 18.2-positive tumor cells. It uniquely engages T cells via the 4-1BB pathway within the tumor's microenvironment, where CLDN18.2 is abundantly expressed. This innovative approach ensures strong tumor binding and anti-tumor efficacy while aiming to reduce liver toxicity and systemic effects usually associated with other 4-1BB-focused therapies.
Notably, Givastomig has received Orphan Drug Designation from the U.S. FDA for treating gastric cancer, which includes cancers at the gastroesophageal junction. Currently, an ongoing Phase 1b study is exploring its combination with standard-of-care approaches, including nivolumab and chemotherapy, for treatment-naïve patients dealing with gastric cancers.
Collaborative Development and Partnership
I-Mab is engaged in a global partnership with ABL Bio to advance the development of Givastomig. While I-Mab leads the program and retains equal rights worldwide, the partnership explicitly excludes regions such as China and South Korea. This collaboration emphasizes I-Mab's strategy to enhance cancer treatment options on a global scale.
About I-Mab
I-Mab (NASDAQ: IMAB) is a dedicated biotech company based in the U.S., committed to innovating immunotherapies aimed at treating various cancers. With established operations situated in key locations, I-Mab strives to develop groundbreaking treatments and leverage its expertise in the field of oncology.
I-Mab Investor & Media Contacts
For inquiries, you may reach Tyler Ehler, Senior Director of Investor Relations, for more information related to I-Mab's initiatives.
Frequently Asked Questions
What is the main focus of I-Mab's presentation at SITC 2024?
I-Mab will present significant data on the optimized dose estimation of Givastomig, a bispecific antibody targeting cancer cells.
When will I-Mab's session occur during the SITC conference?
The presentation session is scheduled for November 9, 2024, with timings from 9:00 am CDT to 8:30 pm CDT.
What makes Givastomig unique?
Givastomig uniquely targets Claudin18.2-positive cells, activating T cells specifically in tumor environments, which minimizes systemic side effects.
What designation has Givastomig received from the FDA?
Givastomig has been granted Orphan Drug Designation for its treatment of gastric cancer, including gastroesophageal junction cancers.
Is there an ongoing trial involving Givastomig?
Yes, a Phase 1b trial is currently evaluating its effectiveness in combination with nivolumab and chemotherapy for treatment-naïve gastric cancer patients.
